Picture
SEARCH
What are you looking for?
Need help finding what you are looking for? Contact Us
Compare

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1373955

Cover Image

PUBLISHER: Fairfield Market Research | PRODUCT CODE: 1373955

Pharmaceutical Elixir Market - Global Pharmaceutical Elixir Industry Analysis, Size, Share, Growth, Trends, Regional Outlook, and Forecast 2023-2030 -

PUBLISHED:
PAGES: 190 Pages
DELIVERY TIME: 2-5 business days
SELECT AN OPTION
PPT Slides/PDF & Excel (Enterprise License)
USD 4995

Add to Cart

Pharmaceutical Elixir Market to Witness Exponential Growth, Reaching US$13 Billion by 2030

The global pharmaceutical elixir market is poised for remarkable growth in the coming years, with market valuation expected to surge from US$7.1 billion in 2022 to approximately US$13 billion by 2030. This robust growth is anticipated to be driven by key factors such as the rising prevalence of chronic diseases, an aging population, and the ever-expanding global healthcare industry.

Key Market Trends

1. Growing Prevalence of Chronic Diseases and Aging Population: Chronic conditions like diabetes, cancer, cardiovascular diseases, and respiratory ailments are affecting a significant portion of the global population. Pharmaceutical elixirs offer an effective and convenient mode of drug administration, ensuring patient compliance, especially among the elderly and pediatric populations. With the aging population on the rise, the demand for pharmaceutical elixirs is steadily increasing.

2. Expanding Global Healthcare Expenditure: As countries allocate more resources to healthcare, individuals gain greater access to healthcare services and pharmaceuticals, including elixirs. Rising healthcare spending by governments, insurance providers, and individuals amplifies the affordability and accessibility of pharmaceutical elixirs, leading to higher consumption.

3. Rapid Growth of Non-Medicated Elixirs: Non-medicated elixirs are gaining popularity within the pharmaceutical sector due to increasing consumer demand for natural and holistic remedies. These elixirs offer a non-pharmacological approach to health and wellness, appealing to individuals seeking alternative solutions and minimal side effects.

4. Hospital Pharmacies Adopting Elixirs: Hospital pharmacies are expanding their focus on pharmaceutical elixirs to provide customized, patient-specific formulations. This trend arises from the need for precise dosage control and individualized treatments, ensuring optimal medication delivery and therapeutic outcomes in clinical settings.

5. Asia Pacific Region Witnessing Fastest Growth: The Asia Pacific region is experiencing the fastest compound annual growth rate (CAGR) in pharmaceutical elixirs due to increasing healthcare access, a burgeoning middle-class population, and a shift towards herbal and traditional remedies. These factors are driving demand for elixirs in this rapidly growing market.

Challenges and Opportunities

Supply Chain Disruptions: The pharmaceutical elixir market faces substantial hurdles due to supply chain interruptions caused by natural catastrophes, pandemics, or geopolitical problems. These disruptions may impact elixir supply and pricing, necessitating a robust and effective supply chain to guarantee a regular and dependable supply of pharmaceutical elixirs.

Stringent Regulatory Environment: Stringent regulations pose a significant challenge to the pharmaceutical elixir market. Compliance requires extensive testing, documentation, and adherence to evolving guidelines, increasing development costs and timelines. Navigating this complex regulatory landscape and securing necessary approvals are essential but challenging for companies operating in the pharmaceutical elixir market.

Advanced Formulations and Digital Health Integration: Advanced formulations, such as nanotechnology and digital health integration, are driving innovation in the pharmaceutical elixir market. These trends aim to enhance drug effectiveness, reduce side effects, and offer patients more convenient and targeted treatment options.

Personalized Medicine: Personalized medicine is another pivotal trend in the pharmaceutical elixir market, involving the tailoring of elixir formulations to individual patient profiles. This approach enhances treatment efficacy, reduces adverse reactions, and improves patient outcomes.

Regional Dominance

North America: North America leads the pharmaceutical elixir market due to its highly developed healthcare infrastructure, large aging population, and robust regulatory frameworks. The region's emphasis on healthcare and pharmaceutical innovation contributes to its dominance.

Asia Pacific: The Asia Pacific region is the fastest-growing market for pharmaceutical elixirs, driven by a rapidly expanding population, rising income levels, and increasing healthcare access. Advancements in healthcare infrastructure and digitalization further contribute to its remarkable growth.

Key Market Players

Some of the key players in the global pharmaceutical elixir market include Pfizer Inc., Novartis AG, Roche Holding AG, Johnson & Johnson, Merck & Co, Sanofi SA, GlaxoSmithKline Plc, AstraZeneca Plc, Eli Lilly and Company, Bristol-Myers Squibb Company, Gilead Sciences, Inc., AbbVie Inc, Bayer AG, Biogen Inc., Moderna Inc., and more.

Conclusion

The global pharmaceutical elixir market is on a growth trajectory, driven by the increasing demand for natural remedies, the aging population, and expanding healthcare access. Challenges such as supply chain disruptions and regulatory complexities are met with opportunities in advanced formulations, digital health integration, and personalized medicine. The market's future looks promising as it continues to innovate and cater to diverse healthcare needs.

Table of Contents

1. Executive Summary

  • 1.1. Global Pharmaceutical Elixir Market Snapshot
  • 1.2. Future Projections
  • 1.3. Key Market Trends
  • 1.4. Regional Snapshot, by Value, 2022
  • 1.5. Analyst Recommendations

2. Market Overview

  • 2.1. Market Definitions and Segmentations
  • 2.2. Market Dynamics
    • 2.2.1. Drivers
    • 2.2.2. Restraints
    • 2.2.3. Market Opportunities
  • 2.3. Value Chain Analysis
  • 2.4. Porter's Five Forces Analysis
  • 2.5. Covid-19 Impact Analysis
    • 2.5.1. Supply
    • 2.5.2. Demand
  • 2.6. Impact of Ukraine-Russia Conflict
  • 2.7. Economic Overview
    • 2.7.1. World Economic Projections
  • 2.8. PESTLE Analysis

3. Global Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 3.1. Global Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 3.1.1. Key Highlights
      • 3.1.1.1. Non-Medicated Elixirs
      • 3.1.1.2. Medicated Elixirs
  • 3.2. Global Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 3.2.1. Key Highlights
      • 3.2.1.1. Hospital Pharmacies
      • 3.2.1.2. Retail Pharmacies
      • 3.2.1.3. Online Sales
  • 3.3. Global Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 3.3.1. Key Highlights
      • 3.3.1.1. Hospitals
      • 3.3.1.2. Clinics
      • 3.3.1.3. Others
  • 3.4. Global Pharmaceutical Elixir Market Outlook, by Region, Value (US$ Bn), 2018 - 2030
    • 3.4.1. Key Highlights
      • 3.4.1.1. North America
      • 3.4.1.2. Europe
      • 3.4.1.3. Asia Pacific
      • 3.4.1.4. Latin America
      • 3.4.1.5. Middle East & Africa

4. North America Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 4.1. North America Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 4.1.1. Key Highlights
      • 4.1.1.1. Non-Medicated Elixirs
      • 4.1.1.2. Medicated Elixirs
  • 4.2. North America Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 4.2.1. Key Highlights
      • 4.2.1.1. Hospital Pharmacies
      • 4.2.1.2. Retail Pharmacies
      • 4.2.1.3. Online Sales
  • 4.3. North America Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 4.3.1. Key Highlights
      • 4.3.1.1. Hospitals
      • 4.3.1.2. Clinics
      • 4.3.1.3. Others
    • 4.3.2. BPS Analysis/Market Attractiveness Analysis
  • 4.4. North America Pharmaceutical Elixir Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 4.4.1. Key Highlights
      • 4.4.1.1. U.S. Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 4.4.1.2. U.S. Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.4.1.3. U.S. Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 4.4.1.4. U.S. Pharmaceutical Elixir Market End Use, Value (US$ Bn), 2018 - 2030
      • 4.4.1.5. Canada Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 4.4.1.6. Canada Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 4.4.1.7. Canada Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 4.4.1.8. Canada Pharmaceutical Elixir Market End Use, Value (US$ Bn), 2018 - 2030
    • 4.4.2. BPS Analysis/Market Attractiveness Analysis

5. Europe Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 5.1. Europe Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 5.1.1. Key Highlights
      • 5.1.1.1. Non-Medicated Elixirs
      • 5.1.1.2. Medicated Elixirs
  • 5.2. Europe Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 5.2.1. Key Highlights
      • 5.2.1.1. Hospital Pharmacies
      • 5.2.1.2. Retail Pharmacies
      • 5.2.1.3. Online Sales
  • 5.3. Europe Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 5.3.1. Key Highlights
      • 5.3.1.1. Hospitals
      • 5.3.1.2. Clinics
      • 5.3.1.3. Others
    • 5.3.2. BPS Analysis/Market Attractiveness Analysis
  • 5.4. Europe Pharmaceutical Elixir Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 5.4.1. Key Highlights
      • 5.4.1.1. Germany Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.2. Germany Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.3. Germany Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.4. U.K. Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.5. U.K. Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.6. U.K. Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.7. France Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.8. France Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.9. France Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.10. Italy Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.11. Italy Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.12. Italy Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.13. Turkey Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.14. Turkey Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.15. Turkey Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.16. Russia Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.17. Russia Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.18. Russia Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 5.4.1.19. Rest of Europe Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 5.4.1.20. Rest of Europe Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 5.4.1.21. Rest of Europe Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
    • 5.4.2. BPS Analysis/Market Attractiveness Analysis

6. Asia Pacific Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 6.1. Asia Pacific Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 6.1.1. Key Highlights
      • 6.1.1.1. Non-Medicated Elixirs
      • 6.1.1.2. Medicated Elixirs
  • 6.2. Asia Pacific Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 6.2.1. Key Highlights
      • 6.2.1.1. Hospital Pharmacies
      • 6.2.1.2. Retail Pharmacies
      • 6.2.1.3. Online Sales
  • 6.3. Asia Pacific Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 6.3.1. Key Highlights
      • 6.3.1.1. Hospitals
      • 6.3.1.2. Clinics
      • 6.3.1.3. Others
    • 6.3.2. BPS Analysis/Market Attractiveness Analysis
  • 6.4. Asia Pacific Pharmaceutical Elixir Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 6.4.1. Key Highlights
      • 6.4.1.1. China Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.2. China Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.3. China Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 6.4.1.4. Japan Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.5. Japan Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.6. Japan Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 6.4.1.7. South Korea Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.8. South Korea Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.9. South Korea Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 6.4.1.10. India Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.11. India Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.12. India Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 6.4.1.13. Southeast Asia Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.14. Southeast Asia Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.15. Southeast Asia Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 6.4.1.16. Rest of Asia Pacific Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 6.4.1.17. Rest of Asia Pacific Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 6.4.1.18. Rest of Asia Pacific Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
    • 6.4.2. BPS Analysis/Market Attractiveness Analysis

7. Latin America Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 7.1. Latin America Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 7.1.1. Key Highlights
      • 7.1.1.1. Non-Medicated Elixirs
      • 7.1.1.2. Medicated Elixirs
  • 7.2. Latin America Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 7.2.1. Key Highlights
      • 7.2.1.1. Hospital Pharmacies
      • 7.2.1.2. Retail Pharmacies
      • 7.2.1.3. Online Sales
  • 7.3. Latin America Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 7.3.1. Key Highlights
      • 7.3.1.1. Hospitals
      • 7.3.1.2. Clinics
      • 7.3.1.3. Others
    • 7.3.2. BPS Analysis/Market Attractiveness Analysis
  • 7.4. Latin America Pharmaceutical Elixir Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 7.4.1. Key Highlights
      • 7.4.1.1. Brazil Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.2. Brazil Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.3. Brazil Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 7.4.1.4. Mexico Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.5. Mexico Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.6. Mexico Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 7.4.1.7. Argentina Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.8. Argentina Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.9. Argentina Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 7.4.1.10. Rest of Latin America Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 7.4.1.11. Rest of Latin America Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 7.4.1.12. Rest of Latin America Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
    • 7.4.2. BPS Analysis/Market Attractiveness Analysis

8. Middle East & Africa Pharmaceutical Elixir Market Outlook, 2018 - 2030

  • 8.1. Middle East & Africa Pharmaceutical Elixir Market Outlook, by Type, Value (US$ Bn), 2018 - 2030
    • 8.1.1. Key Highlights
      • 8.1.1.1. Non-Medicated Elixirs
      • 8.1.1.2. Medicated Elixirs
  • 8.2. Middle East & Africa Pharmaceutical Elixir Market Outlook, by Distribution Channel, Value (US$ Bn), 2018 - 2030
    • 8.2.1. Key Highlights
      • 8.2.1.1. Hospital Pharmacies
      • 8.2.1.2. Retail Pharmacies
      • 8.2.1.3. Online Sales
  • 8.3. Middle East & Africa Pharmaceutical Elixir Market Outlook, by End-use, Value (US$ Bn), 2018 - 2030
    • 8.3.1. Key Highlights
      • 8.3.1.1. Hospitals
      • 8.3.1.2. Clinics
      • 8.3.1.3. Others
    • 8.3.2. BPS Analysis/Market Attractiveness Analysis
  • 8.4. Middle East & Africa Pharmaceutical Elixir Market Outlook, by Country, Value (US$ Bn), 2018 - 2030
    • 8.4.1. Key Highlights
      • 8.4.1.1. GCC Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.2. GCC Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.3. GCC Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 8.4.1.4. South Africa Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.5. South Africa Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.6. South Africa Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 8.4.1.7. Egypt Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.8. Egypt Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.9. Egypt Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 8.4.1.10. Nigeria Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.11. Nigeria Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.12. Nigeria Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
      • 8.4.1.13. Rest of Middle East & Africa Pharmaceutical Elixir Market by Type, Value (US$ Bn), 2018 - 2030
      • 8.4.1.14. Rest of Middle East & Africa Pharmaceutical Elixir Market Distribution Channel, Value (US$ Bn), 2018 - 2030
      • 8.4.1.15. Rest of Middle East & Africa Pharmaceutical Elixir Market End-use, Value (US$ Bn), 2018 - 2030
    • 8.4.2. BPS Analysis/Market Attractiveness Analysis

9. Competitive Landscape

  • 9.1. End-use vs Distribution Channel Heatmap
  • 9.2. Manufacturer vs Distribution Channel Heatmap
  • 9.3. Company Market Share Analysis, 2022
  • 9.4. Competitive Dashboard
  • 9.5. Company Profiles
    • 9.5.1. Pfizer Inc.
      • 9.5.1.1. Company Overview
      • 9.5.1.2. Product Portfolio
      • 9.5.1.3. Financial Overview
      • 9.5.1.4. Business Strategies and Development
    • 9.5.2. Novartis AG
      • 9.5.2.1. Company Overview
      • 9.5.2.2. Product Portfolio
      • 9.5.2.3. Financial Overview
      • 9.5.2.4. Business Strategies and Development
    • 9.5.3. Roche Holding AG
      • 9.5.3.1. Company Overview
      • 9.5.3.2. Product Portfolio
      • 9.5.3.3. Financial Overview
      • 9.5.3.4. Business Strategies and Development
    • 9.5.4. Johnson & Johnson
      • 9.5.4.1. Company Overview
      • 9.5.4.2. Product Portfolio
      • 9.5.4.3. Financial Overview
      • 9.5.4.4. Business Strategies and Development
    • 9.5.5. Merck & Co., Inc
      • 9.5.5.1. Company Overview
      • 9.5.5.2. Product Portfolio
      • 9.5.5.3. Financial Overview
      • 9.5.5.4. Business Strategies and Development
    • 9.5.6. Sanofi S.A.
      • 9.5.6.1. Company Overview
      • 9.5.6.2. Product Portfolio
      • 9.5.6.3. Financial Overview
      • 9.5.6.4. Business Strategies and Development
    • 9.5.7. GlaxoSmithKline plc
      • 9.5.7.1. Company Overview
      • 9.5.7.2. Product Portfolio
      • 9.5.7.3. Financial Overview
      • 9.5.7.4. Business Strategies and Development
    • 9.5.8. AstraZeneca plc
      • 9.5.8.1. Company Overview
      • 9.5.8.2. Product Portfolio
      • 9.5.8.3. Financial Overview
      • 9.5.8.4. Business Strategies and Development
    • 9.5.9. Eli Lilly and Company
      • 9.5.9.1. Company Overview
      • 9.5.9.2. Product Portfolio
      • 9.5.9.3. Financial Overview
      • 9.5.9.4. Business Strategies and Development
    • 9.5.10. Bristol-Myers Squibb Company
      • 9.5.10.1. Company Overview
      • 9.5.10.2. Product Portfolio
      • 9.5.10.3. Financial Overview
      • 9.5.10.4. Business Strategies and Development
    • 9.5.11. Gilead Sciences, Inc.
      • 9.5.11.1. Company Overview
      • 9.5.11.2. Product Portfolio
      • 9.5.11.3. Financial Overview
      • 9.5.11.4. Business Strategies and Development
    • 9.5.12. AbbVie Inc
      • 9.5.12.1. Company Overview
      • 9.5.12.2. Product Portfolio
      • 9.5.12.3. Financial Overview
      • 9.5.12.4. Business Strategies and Development
    • 9.5.13. Bayer AG
      • 9.5.13.1. Company Overview
      • 9.5.13.2. Product Portfolio
      • 9.5.13.3. Financial Overview
      • 9.5.13.4. Business Strategies and Development
    • 9.5.14. Biogen Inc.
      • 9.5.14.1. Company Overview
      • 9.5.14.2. Product Portfolio
      • 9.5.14.3. Financial Overview
      • 9.5.14.4. Business Strategies and Development
    • 9.5.15. Moderna, Inc.
      • 9.5.15.1. Company Overview
      • 9.5.15.2. Product Portfolio
      • 9.5.15.3. Financial Overview
      • 9.5.15.4. Business Strategies and Development

10. Appendix

  • 10.1. Research Methodology
  • 10.2. Report Assumptions
  • 10.3. Acronyms and Abbreviations
Have a question?
Picture

Jeroen Van Heghe

Manager - EMEA

+32-2-535-7543

Picture

Christine Sirois

Manager - Americas

+1-860-674-8796

Questions? Please give us a call or visit the contact form.
Hi, how can we help?
Contact us!